which demonstrated positive results as well as positive trends of key biomarker outcome of neurofilament light chain (NfL) ...

CEO Dr Daniel Vitt joined Proactive's Stephen Gunnion with news of the publication of extended data from the Phase 2 EMPhASIS ...

There are a total of 12 candidates in mid to late-stage trials for ALS poised to enter the market in the next five years.

There has been a breakthrough in the research on the disease amyotrophic lateral sclerosis (ALS). Scientists at Umeå ...

As the Phase III amyotrophic lateral sclerosis pipeline thins out, the ALS community is placing its hopes on earlier-stage ...

A unique autoantibody signature of multiple sclerosis may predict the disease years before individuals become symptomatic.

Scientists have identified new biomarkers that show up in the blood years before symptoms of multiple sclerosis (MS) emerge, ...

In about 1 in 10 cases of MS, the body begins producing a distinctive set of antibodies against its own proteins years before ...

A new study links midlife racial discrimination among Black Americans to increased Alzheimer's biomarkers, highlighting the ...

A lower dose of vidofludimus calcium (IMU-838) was not as effective as higher doses at reducing lesions in people with RRMS, ...

HighlightsATH434-201 Phase 2 baseline data confirm approach to target biomarkers for slowing disease progressionPresented promising nonclinical ...

Early signs of multiple sclerosis could soon be detected by a simple blood test years before symptoms start to show.